Investment Thesis
Integra LifeSciences faces severe operational distress marked by negative net income (-$4.6M), negative free cash flow (-$5.0M), and interest coverage of 0.8x—unable to service debt from operating income. Anemic 1.5% revenue growth combined with deteriorating profitability trends (-7388.9% EPS decline YoY) and razor-thin operating margins (2.9%) suggest fundamental business challenges requiring urgent restructuring.
Strengths
- Strong short-term liquidity with 3.38x current ratio and 1.95x quick ratio
- Adequate cash balance of $236.8M provides operational runway
- Moderate leverage at 0.69x Debt/Equity ratio limits immediate solvency risk
Risks
- Interest coverage of 0.8x indicates inability to cover debt service from operating income; relies on cash reserves for debt payments
- Negative free cash flow (-$5.0M) with FCF margin of -1.3% demonstrates the company cannot fund operations and capital needs from internal sources
- Severe profitability deterioration with -$4.6M net loss and -7388.9% EPS decline YoY signals operational failure not temporary setback
- Stagnant revenue growth of 1.5% YoY combined with negative margins indicates loss of competitive position in medical devices sector
- Operating cash flow of $9.8M (2.5% margin) barely covers operations; insufficient cash generation for debt service and CapEx
Key Metrics to Watch
- Interest coverage ratio—critical threshold; must exceed 1.5x to avoid covenant violations
- Free cash flow trend—must achieve sustained positive FCF to avoid liquidity crisis
- Operating margin expansion—currently 2.9% is unsustainable; needs path to 8%+ minimum
- Revenue growth acceleration—1.5% insufficient; requires 5%+ to demonstrate market recovery
- Net income path to breakeven and profitability—currently negative loss position
Financial Metrics
Revenue
391.9M
Net Income
-4.6M
EPS (Diluted)
$-0.06
Free Cash Flow
-5.0M
Total Assets
3.6B
Cash
236.8M
Profitability Ratios
Gross Margin
217.1%
Operating Margin
2.9%
Net Margin
-1.2%
ROE
-0.4%
ROA
-0.1%
FCF Margin
-1.3%
Balance Sheet & Liquidity
Current Ratio
3.38x
Quick Ratio
1.95x
Debt/Equity
0.69x
Debt/Assets
70.9%
Interest Coverage
0.84x
Long-term Debt
716.9M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T20:28:32.897104 |
Data as of: 2026-03-31 |
Powered by Claude AI